Combination Drugs Diagnostics Market- Complete Study of Current Trends and Opportunities in Global Pharmaceutical Industry

Submitted by: Submitted by

Views: 10

Words: 585

Pages: 3

Category: Business and Industry

Date Submitted: 05/11/2016 12:53 AM

Report This Essay

Combination drug also referred to as fixed dose combination (FDC), is a formulation which includes two or more active pharmaceutical ingredients (APIs). The dosage is distributed in certain fixed doses. Initially, fixed dose combination products were produced for targeting single diseases for example antiretroviral combination drugs were manufactured for targeting AIDS. However, with the advancements, in research and development activities currently combination drugs are being manufactured for targeting multiple disease conditions such as Exforge (amlodipine/valsartan) or Caduet (atorvastatin/amlodipine). Improved medication compliance by reducing the pill burden of patient and ability to compose combined profiles (pharmacokinetics, adverse effects and effects) that may be limited to single dosage form are some of the advantages associated with uptake of combination drugs.

Request For Report Brochure:http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=4742

Factors such as increase in geriatric population, investment in R&D and improved understanding of the nature of diseases are driving the combination drugs diagnostic market growth globally. Since, aged population is more prone to infectious disease therefore; increase in geriatric population will likely increase the demand for combination drugs diagnostics market worldwide. Additionally, as per the World Health Organization, by 2020 nearly 14.1% of the world population will suffer from neurologic disorders which would further lure manufacturers for the production of combination drugs. Similarly, as per American Diabetes Association, in 2011 25.8 million Americans were diagnosed with diabetes and total cost of treatment reached USD 245 billion. Hence, to effectively address the needs of patients, combination drugs are being launched in the market. Atripla, Combivir, Kaletra, Truvada, Trizivir, Excalia, Symbax, Contrave, Symbicort, Advair/ Seretide, Flutiform, Janumet, Duovent,...